In the world of income investing, dividends reign supreme. Treasuries and CDs are offering historically low yields and are no longer considered the ultra-safe cash generators that they once were.
---Recommended Link--- This Michigan Couple Collects A $40,000 'Bonus' Every YearVernie and her husband were hard-working farmers all their lives. But they finally retired. And unlike their friends, who have to supplement their meager Social Security checks with part-time jobs just to make ends meet, Vernie says they're collecting about $40,000 a year in extra income. "We bought a new car last year and could pay for it." Does that sound like a retirement you'd be looking forward to? If so, click here to learn their secret.
There's a little-known group of stocks that offer huge dividend payouts, but their yields are not displayed to the public on financial websites like Yahoo! Finance or Morningstar. This phenomenon is due to a glitch in the way the financial media reports certain companies' financial information.
Top 5 Heal Care Stocks To Watch For 2019: New York Times Company (NYT)
Advisors' Opinion:- [By Daniel Sparks]
The New York Times (NYSE:NYT) impressed investors earlier this week when it reported stronger-than-expected fourth-quarter results. The stock surged nearly 13% on Wednesday as investors digested the implications of the company's robust performance and management's optimism for the company's future.
- [By Daniel Sparks]
Following a surge in the The New York Times' (NYSE:NYT) stock since the "Trump-bump" effect and an impressive first quarter earlier this year, the newspaper failed to impress last week when it reported its second-quarter results. Suppressed advertising revenue and slowing growth in digital subscribers were reminders of some of the risks to owning shares of the evolving company.
- [By Natalie Walters]
The New York Times Co. (NYSE:NYT) has been under additional scrutiny since the 2016 election as President Donald Trump continues to call out the flagship publication for what he deems "fake news." But the company is holding up under the spotlight, reporting quarterly revenue of $413.9 million, up from $398 million in the year-ago quarter.
- [By Shane Hupp]
New York Times Co (NYSE:NYT) has earned an average recommendation of “Hold” from the six brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $21.67.
Top 5 Heal Care Stocks To Watch For 2019: Nabriva Therapeutics AG(NBRV)
Advisors' Opinion:- [By Ethan Ryder]
Shares of Nabriva Therapeutics PLC – (NASDAQ:NBRV) traded up 12.5% on Wednesday . The stock traded as high as $3.10 and last traded at $3.06. 1,168,690 shares were traded during mid-day trading, an increase of 169% from the average session volume of 434,354 shares. The stock had previously closed at $2.72.
- [By Ethan Ryder]
Nabriva Therapeutics PLC – (NASDAQ:NBRV) – Analysts at Wedbush boosted their Q2 2018 earnings per share estimates for Nabriva Therapeutics in a research note issued to investors on Monday, July 30th. Wedbush analyst R. Driscoll now forecasts that the biotechnology company will post earnings per share of ($0.44) for the quarter, up from their prior estimate of ($0.46). Wedbush also issued estimates for Nabriva Therapeutics’ Q3 2018 earnings at ($0.17) EPS, Q4 2018 earnings at ($0.26) EPS, FY2018 earnings at ($1.24) EPS, FY2019 earnings at ($1.11) EPS, FY2020 earnings at ($0.66) EPS, FY2021 earnings at ($0.24) EPS and FY2022 earnings at $0.52 EPS.
- [By Brian Feroldi]
After the company announced top-line data from an important phase 3 trial, shares of Nabriva Therapeutics (NASDAQ:NBRV), a clinical-stage biotech focused on next-generation antibiotics, fell as much as 14% in morning trading on Monday. As of 11:20 a.m. EDT, the stock was down 9%.
- [By Logan Wallace]
Nabriva Therapeutics PLC – (NASDAQ:NBRV) shares saw strong trading volume on Monday . 908,177 shares traded hands during mid-day trading, an increase of 63% from the previous session’s volume of 558,242 shares.The stock last traded at $2.04 and had previously closed at $1.91.
- [By Ethan Ryder]
Nabriva Therapeutics PLC – (NASDAQ:NBRV) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $4.20 and last traded at $4.39, with a volume of 8914 shares. The stock had previously closed at $4.29.
- [By Ethan Ryder]
Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.23. Nabriva Therapeutics had a negative return on equity of 79.30% and a negative net margin of 600.34%. The firm had revenue of $7.55 million for the quarter, compared to analyst estimates of $1.27 million. equities analysts anticipate that Nabriva Therapeutics will post -1.9 EPS for the current fiscal year.
Top 5 Heal Care Stocks To Watch For 2019: Olympic Steel Inc.(ZEUS)
Advisors' Opinion:- [By Stephan Byrd]
Olympic Steel, Inc. (NASDAQ:ZEUS) – Jefferies Financial Group boosted their Q2 2018 earnings per share (EPS) estimates for Olympic Steel in a report released on Tuesday, July 10th. Jefferies Financial Group analyst S. Rosenfeld now anticipates that the basic materials company will earn $1.01 per share for the quarter, up from their previous forecast of $0.90. Jefferies Financial Group also issued estimates for Olympic Steel’s Q3 2018 earnings at $0.50 EPS, Q4 2018 earnings at $0.09 EPS, FY2018 earnings at $2.29 EPS and FY2019 earnings at $2.37 EPS.
- [By Joseph Griffin]
Olympic Steel (NASDAQ:ZEUS) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.
- [By Stephan Byrd]
Headlines about Olympic Steel (NASDAQ:ZEUS) have been trending somewhat positive on Tuesday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Olympic Steel earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the basic materials company an impact score of 47.5465348320487 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Top 5 Heal Care Stocks To Watch For 2019: Sibanye Gold Limited(SBGL)
Advisors' Opinion:- [By Lisa Levin] Gainers vTv Therapeutics Inc. (NASDAQ: VTVT) shares surged 115 percent to $2.56. Seadrill Limited (NYSE: SDRL) gained 77 percent to $0.3935. On Tuesday, a U.S. court approved the company's plan to exit Chapter 11 bankruptcy that includes raising around $1 billion in new debt and equity through a rights offering which will be led by its biggest shareholder. DropCar, Inc. (NASDAQ: DCAR) shares climbed 21.4 percent to $2.3301 after the company issued a preliminary Q1 update on its enterprise automotive business. The company disclosed that Q1 B2B automotive volumes rose 163 percent year-over-year. Teligent, Inc. (NASDAQ: TLGT) shares jumped 19.7 percent to $3.615 following the FDA approval of Clobetasol Propionate Cream USP, 0.05%. IZEA, Inc. (NASDAQ: IZEA) surged 19.1 percent to $2.62. IZEA posted a Q4 net loss of $743,000 on sales of $6.8 million. SunPower Corporation (NASDAQ: SPWR) shares gained 15.2 percent to $9.6180. SunPower announced plans to acquire SolarWorld Americas. LexinFintech Holdings Ltd. (NASDAQ: LX) climbed 10.2 percent to $15.20. CounterPath Corporation (NASDAQ: CPAH) shares rose 8.8 percent to $3.0033. Semiconductor Manufacturing International Corporation (NYSE: SMI) gained 8.2 percent to $6.685 after falling 0.80 percent on Tuesday. Energy XXI Gulf Coast, Inc. (NASDAQ: EGC) shares climbed 7.2 percent to $5.93. Textron Inc. (NYSE: TXT) shares rose 6.7 percent to $63.96 after the company reported stronger-than-expected earnings for its first quarter. Sibanye Gold Limited (NYSE: SBGL) gained 6.5 percent to $3.59 after dropping 4.53 percent on Tuesday. Calithera Biosciences, Inc. (NASDAQ: CALA) rose 6.3 percent to $6.75 after the company disclosed that the FDA has granted Fast Track designation to CB-839 in combination with cabozantinib for treatment of patients with advanced renal cell carcinoma. CSX Corporation (NASDAQ: CSX) gained 6.1 percent to $60.01 after reporting upbeat quarterly earnings
- [By Logan Wallace]
Shares of Sibanye Gold Ltd (NYSE:SBGL) have been assigned a consensus rating of “Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company.
- [By Jim Robertson]
Greenfield African countries like Burkina Faso are starting to look very attractive for mining as the South African mining sector continues to face numerous headwinds. This week, shares of major South African mining stock like DRDGOLD Limited (NYSE: DRD), Gold Fields Limited (NYSE: GFI), Harmony Gold Mining Co (NYSE: HMY) and Sibanye-Stillwater (NYSE: SBGL) fell off amid news about further company retrenchments and a warning from the ruling African National Congress (ANC) against doing more job cuts.
- [By Maxx Chatsko]
Shares of Sibanye-Stillwater (NYSE:SBGL), formerly Sibanye Gold Limited, fell over 11% today after news that a worker died at its Driefontein mining operation in South Africa. As reported by News24, over 20 workers have died at mines owned by the company this year, which is nearly half of all mining industry deaths in the country.
Top 5 Heal Care Stocks To Watch For 2019: Jinpan International Limited(JST)
Advisors' Opinion:- [By Max Byerly]
Hauck & Aufhaeuser set a €58.00 ($67.44) target price on JOST Werke (ETR:JST) in a report issued on Wednesday. The brokerage currently has a buy rating on the stock.
- [By Joseph Griffin]
Warburg Research set a €47.00 ($55.95) price target on JOST Werke (ETR:JST) in a report published on Friday. The firm currently has a buy rating on the stock.
- [By Logan Wallace]
A number of firms have modified their ratings and price targets on shares of JOST Werke (ETR: JST) recently:
5/25/2018 – JOST Werke was given a new €46.00 ($53.49) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock. 5/25/2018 – JOST Werke was given a new €46.00 ($53.49) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock. 5/25/2018 – JOST Werke was given a new €47.00 ($54.65) price target on by analysts at Warburg Research. They now have a “buy” rating on the stock. 5/24/2018 – JOST Werke was given a new €45.00 ($52.33) price target on by analysts at JPMorgan Chase & Co.. They now have a “neutral” rating on the stock. 5/8/2018 – JOST Werke was given a new €46.00 ($53.49) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock. 4/4/2018 – JOST Werke was given a new €47.00 ($54.65) price target on by analysts at Warburg Research. They now have a “buy” rating on the stock.Shares of JOST Werke traded down €0.15 ($0.17), hitting €38.10 ($44.30), during mid-day trading on Friday, according to MarketBeat. 8,510 shares of the company’s stock were exchanged, compared to its average volume of 35,469. JOST Werke AG has a 52 week low of €27.20 ($31.63) and a 52 week high of €47.50 ($55.23).
- [By Joseph Griffin]
JOST Werke AG (ETR:JST) has earned an average rating of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is €49.33 ($57.36).
- [By Joseph Griffin]
Deutsche Bank set a €46.00 ($53.49) price target on JOST Werke (ETR:JST) in a research report sent to investors on Friday. The firm currently has a buy rating on the stock.
No comments:
Post a Comment